165 related articles for article (PubMed ID: 37686163)
21. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.
Liu M; Zhang L; Li H; Hinoue T; Zhou W; Ohtani H; El-Khoueiry A; Daniels J; O'Connell C; Dorff TB; Lu Q; Weisenberger DJ; Liang G
Hepatology; 2018 Oct; 68(4):1412-1428. PubMed ID: 29774579
[TBL] [Abstract][Full Text] [Related]
22. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
24. DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.
Borghesan M; Fusilli C; Rappa F; Panebianco C; Rizzo G; Oben JA; Mazzoccoli G; Faulkes C; Pata I; Agodi A; Rezaee F; Minogue S; Warren A; Peterson A; Sedivy JM; Douet J; Buschbeck M; Cappello F; Mazza T; Pazienza V; Vinciguerra M
Cancer Res; 2016 Feb; 76(3):594-606. PubMed ID: 26772755
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Jung N; Won JK; Kim BH; Suh KS; Jang JJ; Kang GH
J Korean Med Sci; 2012 Jun; 27(6):594-604. PubMed ID: 22690089
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
27. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
29. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
Cheng H; Wang S; Huang A; Ma J; Gao D; Li M; Chen H; Guo K
Cancer Biol Ther; 2023 Dec; 24(1):1-9. PubMed ID: 36482717
[TBL] [Abstract][Full Text] [Related]
30. OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.
Wu D; Yang X; Peng H; Guo D; Zhao W; Zhao C; Zhou X
Carcinogenesis; 2017 Sep; 38(9):910-919. PubMed ID: 28911005
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
32. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
33. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721.
Fan H; Zhao Z; Quan Y; Xu J; Zhang J; Xie W
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):952-61. PubMed ID: 18049164
[TBL] [Abstract][Full Text] [Related]
34. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
35. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
Front Immunol; 2021; 12():712351. PubMed ID: 34504494
[TBL] [Abstract][Full Text] [Related]
36. Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.
Ilyas A; Hashim Z; Zarina S
Mol Cell Biochem; 2015 Jul; 405(1-2):53-61. PubMed ID: 25854900
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
38. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
39. GOLM1 exacerbates CD8
Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
[TBL] [Abstract][Full Text] [Related]
40. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]